• 1
    Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000; 43: 249259.
  • 2
    Sadick NS. The impact of cosmetic interventions on quality of life. Dermatol Online J 2008; 14: 2.
  • 3
    Pickett AM, Hambleton P. Dose standardisation of botulinum toxin. Lancet 1994; 344: 474475.
  • 4
    Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 2008; 34: 18.
  • 5
    Rzany B, Dill-Müller D, Grablowitz D, Heckmann M, Carid D. Repeated botulinum toxin A injections for the treatment of lines in the upper face: A retrospective study of 4103 treatments in 945 patients. Dermatol Surg 2007; 33: S18S25.
  • 6
    Markey AC. Dysport. Dermatol Clin 2004; 22: 213219.
  • 7
    Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 1995; 18: 720729.
  • 8
    Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 1998; 64: 751757.
  • 9
    De Maio M, Rzany B. Botulinum Toxin in Aesthetic Medicine. Springer, Heidelberg, 2007.
  • 10
    Ascher B, Landau M, Rossi B. Injection treatments in cosmetic surgery. Informa Healthcare, London. Editor 2008
  • 11
    Carruthers A, Carruthers J. A single-center, dose-comparison, pilot study of botulinum neurotoxin A in female patients with upper facial rhytides: safety and efficacy. J Am Acad Dermatol 2009; 60: 972979.
  • 12
    Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet. Dermatol Surg 2005; 31: 257262.
  • 13
    Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow’s feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 2009; 35: 14781486.
  • 14
    Flynn TC, Carruthers JA, Carruthers JA, Clark RE II. Botulinum A toxin (BOTOX) in the lower eyelid:dose-finding study. Dermatol Surg 2003; 29: 943950.
  • 15
    Rzany B, Fratila A, Heckmann M. Expertentrffen zur Anwendung von Botulinumtoxin A in der Ästhetischen Dermatologie. Kosmetische Medizin 2005; 3: 18.
  • 16
    Sommer B, Bergfeld D, Sattler G. Consensus recommendations on the use of botulinum toxin type A in aesthetic medicine. J Dtsch Dermatol Ges 2007; 5(Suppl. 1): S1S29.
  • 17
    Carruthers J, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 2004; 114(Suppl. 1): S1S22.
  • 18
    Carruthers J, Glogau RG, Blitzer A. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies – consensus recommendations. Plast Reconstr Surg 2008; 121: S5S30.
  • 19
    Lewis CM, Lavell S, Simpson MF. Patient selection and patient satisfaction. Clin Plast Surg 1983; 10: 321332.
  • 20
    Ascher B, Zakine B, Kestemont P et al. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthet Surg J 2005; 25: 365375.
  • 21
    Rzany B, Ascher B, Fratila A, Monheit G, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142: 320326.
  • 22
    Moy R, Maas C, Monheit G, Huber MB. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 2009; 11: 7783.
  • 23
    Rubin MG, Dover J, Glogau RG, Goldberg DJ, Goldman MP, Schlessinger J. The efficacy and safety of a new U.S. Botulinum toxin type A in the re-treatment of glabellar lines following open-label treatment. J Drugs Dermatol 2009; 8: 439444.
  • 24
    Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009; 35: 18931901.
  • 25
    Monheit GD, Cohen JL. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol 2009; 61: 421425.
  • 26
    Galderma SA. Azzalure, Summary of Product Characteristic (SmPC). [WWW document] 2008. URL (last accessed: 4 March 2010).
  • 27
    Ipsen Ltd. Dysport, Summary of Product Characteristics (SmPC). [WWW document] 2007 URL (last accessed: 4 March 2010).
  • 28
    Hexsel D, Rutowitsch MS, De Castro LC, Do Prado DZ, Lima MM. Blind multicenter study of the efficacy and safety of injections of a commercial preparation of Botulinum toxin Type A reconstituted up to 15 days before injection. Dermatol Surg 2009; 35: 933939.
  • 29
    Ascher B, Zakine B, Kestemont P, Baspeyras M, Bougara A, Santini J. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223233.
  • 30
    Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33: S51S59.
  • 31
    Kane MA, Rohrich RJ, Narins RS, Monheit GD, Huber MB. Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009; 124: 16191629.
  • 32
    Karsai S, Adrian R, Hammes S, Thimm J, Raulin C. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity. Arch Dermatol 2007; 143: 14471449.
  • 33
    Farahvash MR, Arad S. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience. J Cosmet Dermatol 2007; 6: 152158.
  • 34
    Dewandre L, Voloshchenko I, Trembach A. Etude comparative pilote de l’efficacité et de la durée d’activité de Dysport vs Botox dans les indications esthétiques classiques (front, glabelle, patte d’oie). J Méd Esth et Chir Derm 2003; 118: 101107.